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Sir,
Dr Papagrigoriadis’ main points of criticism of our neoadjuvant
strategy for treatment of rectal cancer are the toxicity of
chemotherapy and subsequent surgery and the potential risk of
overtreating the patient owing to overstaging. We respond as
follows:
1. Neoadjuvant chemoradiotherapy has lower rates of acute
toxicity and late toxicity than adjuvant chemoradiotherapy
regimens of comparable intensity. This was clearly demon-
strated by the German Rectal Cancer Study (Sauer et al, 2004).
All of the studies cited by Dr Papagrigoriadis are trials
investigating intensified neoadjuvant chemoradiotherapy. To
our knowledge, no comparable studies or the corresponding
data on the toxicity of intensified adjuvant chemoradiotherapy
exist. In our opinion, postoperative intensive chemoradio-
therapy is not feasible in light of evidence that an already
investigated adjuvant treatment scheme calling for 5-fluoro-
uracil (5-FU) (2.6gm
 2/24h; weekly) and folinic acid con-
current with radiation ‘should not be recommended for further
use in postoperative adjuvant treatment’ owing to toxicity
reasons (Dencausse et al, 2001).
2. The main goals of intensive chemoradiotherapy are to achieve
higher rates of local control with lower rates of distant
metastasis. Studies by Mitchell’s team and our own suggest
that this is possible (Klautke et al, 2005; Mitchell et al, 2005).
We hope that follow-up studies performed in the scope of the
German Rectal Cancer Study and the PETAC 6 study will
provide a definitive answer to this question.
3. We do not share Dr Papagrigoriadis’ opinion that patients
who undergo resection after neoadjuvant chemoradiotherapy
have a 3–5% higher risk of mortality. Neither the NSABP
R-03 Study nor the German Rectal Cancer Study showed an
overall increase in the rate of perioperative complications
in neoadjuvant treatment arms compared with the adjuvant
treatment arms. Furthermore, a number of phase I and
II studies on intensive neoadjuvant chemoradiotherapy
did not reveal any higher rates of perioperative complica-
tions owing to intensification. More than 100 patients have
received intensive neoadjuvant chemoradiotherapy in
four studies performed at our hospital (Klautke et al,
2006). None of these patients died owing to perioperative
complications.
4. We conscientiously reported on complications associated with
our intensive treatment regimen. Fatalities occurred in two of
28 patients. However, these deaths must be assessed by means
of a differential analysis, which we included in the publication:
One patient died of 5-FU-related toxicity (sudden cardiac
death) – a rare and tragic complication of the drug (Tsavaris
et al, 2002; Alter et al, 2006). This is not attributable to the
treatment sequence and could also happen in an adjuvant
treatment setting.
Another patient developed a dose-limiting toxicity (CTC grade
4 diarrhoea) during the dose-finding stage with capecitabine
and was then transferred to the intensive care unit for safety
reasons. The patient fully recovered from her abdominal
complaints and was supposed to be discharged before the
planned resection surgery but she suddenly developed Kleb-
siella pneumonia and died. This death was associated with
intensive radiochemotherapy (RCT) but could also occur in
adjuvant RCT with 5-FU. It is important to report these
experiences because the occurrence of the dose-limiting toxicity
(grade 4 diarrhoea) means that the administered dose should
no longer be used. The intensity was therefore decreased in the
later studies, and no cases of severe diarrhoea developed. None
of the other 100þ patients who received intensive neoadjuvant
chemoradiotherapy at our hospital died of treatment complica-
tions. By adjusting the capecitabine dosage, with treatment on
days 1–14 and 21–35 separated by a 1-week break in
treatment, we successfully reduced the rate of diarrhoea as an
acute toxicity to a level of roughly 10% (CTC grade 3 diarrhoea)
without decreasing the efficacy of treatment (Klautke et al,
2006).
5. We agree with Dr Papagrigoriadis that overstaging is a problem
associated with a risk of overtreatment. Overstaging occurred
in approximately 20% of patients treated in the German Rectal
Cancer Study. However, the lack of performance of a
pretreatment pelvic MRI examination could be the reason
from some cases of overstaging in this study. In addition,
patients who had sonographically confirmed lymph node
involvement without stage uT3 or uT4 rectal cancer were also
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inclusion in our studies. This diagnosis cannot be made based
on ultrasound evidence of lymph node involvement alone.
We are convinced that consistent use of endosonography and
MRI with additional PET-CT as needed (even if difficult to
perform in the pelvic region), when performed by an
experienced examiner, can significantly reduce the risk of
overstaging.
In summary, we conclude that intensive neoadjuvant chemo-
radiotherapy of UICC stage II and III rectal cancer can produce
promising results with generally acceptable toxicity. The current
evidence suggests that this treatment strategy may improve local
control whereas reducing the rate of distant metastasis. However,
intensive neoadjuvant chemoradiotherapy should be carried out
within the framework of clinical trials designed to demonstrate the
effects of this treatment strategy.
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